Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nexstim OyjSTU:5NX -3.37%61 PS Ratio is 6.58 as of Sep. 07, 2026, which is 133% above its 10-year median of 2.83. GuruFocus rates STU:5NX with a GF Score™ of 61/100 and a GF Value™ of €8.18. The stock has 5 warning signs investors should review. Among 803 Medical Devices & Instruments companies, Nexstim Oyj ranks worse than 80.07% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Nexstim Oyj's share price is €9.45.
Nexstim Oyj's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €1.44. Hence, Nexstim Oyj's PS Ratio for today is 6.58.
The historical rank and industry rank for Nexstim Oyj's PS Ratio or its related term are showing as below:
STU:5NX'
s PS Ratio Range Over the Past 10 Years
Min: 0.11 Med: 2.83 Max: 12.78
Current: 7.52
During the past 13 years, Nexstim Oyj's highest PS Ratio was 12.78. The lowest was 0.11. And the median was 2.83.
STU:5NX's PS Ratio is ranked worse than 80.07% of 803
companies
in the Medical Devices & Instruments industry
Industry Median: 3.02
vs STU:5NX: 7.52
Nexstim Oyj revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Nexstim Oyj was -13.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 5.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 6.60% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -26.30% per year.
During the past 13 years, Nexstim Oyj's highest 3-Year average Revenue per Share Growth Rate was 9.50% per year. The lowest was -63.20% per year. And the median was -22.40% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Nexstim Oyj PS Ratio Related Terms
Nexstim Oyj PS Ratio Historical Data
* Premium members only.
The historical data trend for Nexstim Oyj's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Nexstim Oyj's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nexstim Oyj PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nexstim Oyj's PS Ratio distribution charts can be found below:
* The bar in red indicates where Nexstim Oyj's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Nexstim Oyj's Share Price of today is €9.45.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nexstim Oyj's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was €1.44.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Nexstim Oyj (STU:5NX) has a PS Ratio of 6.58 as of Sep. 07, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Nexstim Oyj and its competitors. This is 133% above median its historical median of 2.83. Over the past decade, Nexstim Oyj's PS Ratio has ranged from 0.11 to 12.78. According to the industry distribution chart, Nexstim Oyj ranks #643 out of 803 companies in the Medical Devices & Instruments industry, placing it in the top 80.1%.
Is Nexstim Oyj's PS Ratio too high?
Nexstim Oyj's current PS Ratio of 6.58 is 133% above median its 10-year median of 2.83. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 12.78. The Medical Devices & Instruments industry median PS Ratio is 3.02. Nexstim Oyj's value of 6.58 is 117.9% above this industry median. Based on the distribution chart, Nexstim Oyj ranks #643 out of 803 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Nexstim Oyj has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Nexstim Oyj's PS Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nexstim Oyj ranks #643 out of 803 companies for PS Ratio. This places Nexstim Oyj in the lower half of its industry. The industry median PS Ratio is 3.02. Nexstim Oyj's value of 6.58 is 117.9% above this benchmark. Historically, Nexstim Oyj's own PS Ratio has ranged from 0.11 to 12.78 over the past decade. While the company's 10-year median is 2.83 vs. the industry median of 3.02, Nexstim Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 3.02, based on 803 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nexstim Oyj's current PS Ratio of 6.58 is 117.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Nexstim Oyj and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 3.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nexstim Oyj's current PS Ratio is 6.58, which is 133% above median its own 10-year median of 2.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexstim Oyj stock overvalued right now?
Nexstim Oyj (STU:5NX) has a current PS Ratio of 6.58. The stock's GF Value™ is €8.18, compared to a current price of €9.45 — trading 15.5% above its estimated fair value. The current PS Ratio is 6.58, which is 133% above median its 10-year median of 2.83 and 117.9% above the Medical Devices & Instruments industry median of 3.02. Nexstim Oyj's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Nexstim Oyj (STU:5NX), the current PS Ratio is 6.58 as of Sep. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nexstim Oyj (STU:5NX) Overvalued in 2026?
Based on GuruFocus' analysis, Nexstim Oyj stock appears to be overvalued.
The current stock price of €9.45 is trading 15.5% above its estimated GF Value™ of €8.18.
Key valuation signals for STU:5NX:
PS Ratio: 6.58 (133% above median its 10-year median of 2.83)
GF Value™: €8.18 vs. price of €9.45 (15.5% above fair value)
Industry Position: 117.9% above the Medical Devices & Instruments median (#643 of 803)
No single metric tells the full story. See the STU:5NX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nexstim Oyj is a Finnish medical technology company. It has developed a non-invasive brain-stimulation technology for navigated transcranial magnetic stimulation (nTMS), with sophisticated 3D navigation that provides accurate, personalized targeting of TMS to specific brain areas. The company's diagnostic business focuses on commercializing the NBS System 6, an FDA-cleared, CE-marked navigated TMS system for pre-surgical mapping of the brain's speech and motor cortices. Its therapy business sells the NBS System 6 for the treatment of depressive disorder in the United States, and for the treatment of depression, chronic neuropathic pain, and post-operative rehabilitation of motor deficits of the upper limb, in Europe. Geographically, the firm generates maximum revenue from North America.
61GF Score
Get the complete analysis for STU:5NX
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:5NX has been successfully added to your 
